Statement by Vigmed’s bid committee in relation to the increased public offer by Greiner Bio-One
Helsingborg, 20 April 2017 The independent Vigmed Bid Committee continues to recommend the shareholders to accept the Greiner Bio-One’s public offer.On 27 February 2017, Greiner Bio-One GmbH (“GBO”) announced a public cash offer to the shareholders of Vigmed Holding AB (publ) (“Vigmed”) at the price of SEK 1.00 in cash per share (the “Offer”).On 13 April 2917, GBO announced its decision to increase the Offer consideration to SEK 1.20 in cash per share[1]. The total value of the increased Offer, based on all outstanding 65,749,998 shares in Vigmed, amounts to approximately SEK 78.9